Castle Biosciences (NASDAQ:CSTL) Research Coverage Started at Guggenheim
Guggenheim assumed coverage on shares of Castle Biosciences (NASDAQ:CSTL – Free Report) in a report issued on Thursday, MarketBeat.com reports. The firm issued a buy rating and a $25.00 price target on the stock. Castle Biosciences Stock Down 2.6 % Shares of Castle Biosciences stock opened at $20.07 on Thursday. The firm has a market […]
More Stories
Wall Street Review: Stocks End Week Mixed Amid Bulls-Bears Tug of War
By Panos Mourdoukoutas Equities finished the week mixed as a renewed tug-of-war played out between bullish investors focused on the...
Voting Under Fire: Zelenskyy Weighs Elections in Ukraine, but Wartime Obstacles Remain
By Chris Summers Ukrainian President Volodymyr Zelenskyy said on Dec. 9 he was prepared to hold elections within three months...
Suspect in Taiwan’s Deadly Knife Attack Acted Alone, Police Say
By T.J. Muscaro The man suspected of killing at least three people with a knife and discharging smokebombs in Taipei,...
Trump Reveals 50 State Tour to Celebrate America’s 250th Birthday
By Jacki Thrapp President Donald Trump has announced the U.S. 250 Freedom Tour to celebrate America’s 250th birthday. The tour,...
DOJ Seeking Appeals on Dismissals of Criminal Cases Against James Comey, Letitia James
By Troy Myers The U.S. Department of Justice (DOJ) is appealing the dismissal of a pair of criminal cases against...
Putin Backs Trump’s Peace Effort, Says Russia Accepted Compromises
By Guy Birchall Russian President Vladimir Putin, speaking during his marathon annual news conference on Dec. 19, said he supports...